Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Onconova The Form 4	erapeutics, Inc.								
May 20, 2016)								
FORM							PPROVAL		
	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549				N OMB Number:	3235-0287 January 31, 2005			
Check this box if no longer			F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires:	
subject to Section 16 Form 4 or	Estimated burden ho	Estimated average burden hours per							
Form 4 or Form 5		rsuant to 3	Section 16(a) of the Securities Exchange Act of 1934,					response	. 0.5
obligations may continue. See Instruction 1(b).						npany Act	of 1935 or Secti		
(Print or Type Re	esponses)								
()}	F)								
1. Name and Address of Reporting Person <u>*</u> Reddy E Premkumar			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer			
			Onconova Therapeutics, Inc. [ONTX]				(Check all applicable)		
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			X_ Director 10% Owner Officer (give title Other (specify below) below)			
C/O ONCON THERAPEU	JOVA TICS, INC., 37	5	05/18/2	2016			below)	Delow)	
PHEASANT	RUN								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
NEWTOWN	, PA 18940						_X_ Form filed by Form filed by Person		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned
	2. Transaction Date 2A. Dee (Month/Day/Year) Execution any (Month/			3. Transactio Code (Instr. 8)	ransactionAcquired (A) or Code Disposed of (D)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect
						(A) or	Reported Transaction(s)		
				Code V	Amount	(D) Price	(Instr. 3 and 4)		
Reminder: Repo	rt on a separate line	e for each c	lass of sec	urities bene	ficially ow	ned directly	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if TransactiorDeriv any Code Secur (Month/Day/Year) (Instr. 8) Acqu or Di (D) (Instr		Securities Acquired (A) or Disposed of	ivative Expiration Date urities (Month/Day/Year) uired (A) Disposed of tr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	\$ 0.52	05/18/2016		А	10,000	<u>(1)</u>	05/18/2026	Common Stock	10,000

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
to Porting of the Composition	Director	10% Owner	Officer	Other			
Reddy E Premkumar C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940	Х						
Signatures							
/s/ Ramesh Kumar as attorney-in-fact 05	5/20/2016						
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest over one year in 12 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.